Akari Therapeutics PLC (NASDAQ:AKTX) has earned a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $9.00.
Several research firms have recently issued reports on AKTX. Zacks Investment Research downgraded shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 16th. B. Riley began coverage on shares of Akari Therapeutics in a report on Thursday, February 8th. They set a “neutral” rating and a $3.00 price objective on the stock. Finally, ValuEngine upgraded shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th.
Institutional investors and hedge funds have recently bought and sold shares of the company. Endurant Capital Management LP acquired a new position in shares of Akari Therapeutics during the fourth quarter valued at about $871,000. Hikari Power Ltd increased its holdings in shares of Akari Therapeutics by 152.2% during the third quarter. Hikari Power Ltd now owns 151,334 shares of the biopharmaceutical company’s stock valued at $929,000 after acquiring an additional 91,322 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Akari Therapeutics by 125.0% during the fourth quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock valued at $1,126,000 after acquiring an additional 144,477 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new position in shares of Akari Therapeutics during the fourth quarter valued at about $2,962,000. Hedge funds and other institutional investors own 21.05% of the company’s stock.
Akari Therapeutics (NASDAQ:AKTX) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.91. sell-side analysts forecast that Akari Therapeutics will post -2.5 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Akari Therapeutics PLC (AKTX) Given Average Recommendation of “Hold” by Analysts” was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://baseballnewssource.com/markets/akari-therapeutics-plc-aktx-given-average-recommendation-of-hold-by-analysts/1884634.html.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.